U.S. Markets closed

Today’s Research Reports on Fennec Pharmaceuticals, Aptose Biosciences, TSO3 and ImmunoVaccine

NEW YORK, NY / ACCESSWIRE / May 2, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Fennec Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=FRX.TO

Aptose Biosciences Inc.
https://rdinvesting.com/news/?ticker=APS.TO

TSO3 Inc.
https://rdinvesting.com/news/?ticker=TOS.TO

ImmunoVaccine Inc.
https://rdinvesting.com/news/?ticker=IMV.TO

Fennec's stock edged 0.32% lower Tuesday, to close the day at $15.79. The stock recorded a trading volume of 1,444 shares, which was below its three months average volume of 3,233 shares. In the last year, Fennec's shares have traded in a range of 4.11 - 18.86. The share price has gained 284.18% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $14.86 is greater than its 200-day moving average of $12.74. Shares of Fennec Pharmaceuticals have gained approximately 26.42 percent year-to-date.

Access RDI's Fennec Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=FRX.TO

On Tuesday, shares of Aptose Biosciences recorded a trading volume of 9,320 shares, which was below the three months average volume of 40,191 shares. The stock ended the day 2.39% lower at 4.08. The share price has gained 229.03% from its 52 week low with a 52 week trading range of 1.24 - 5.18. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $4.34 is greater than its 200-day moving average of $3.23. Shares of Aptose Biosciences have gained approximately 46.76 percent year-to-date.

Access RDI's Aptose Biosciences Inc. Research Report at:
https://rdinvesting.com/news/?ticker=APS.TO

TSO3's stock moved 8.43% lower Tuesday, to close the day at $0.76. The stock recorded a trading volume of 283,749 shares, which was above its three months average volume of 173,462 shares. In the last year, TSO3's shares have traded in a range of 0.72 - 3.30. The stock is currently trading 76.97% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $1.01 is below its 200-day moving average of $1.93. Shares of TSO3 have fallen approximately 70.88 percent year-to-date.

Access RDI's TSO3 Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TOS.TO

On Tuesday, shares of ImmunoVaccine recorded a trading volume of 103,940 shares, which was above the three months average volume of 78,850 shares. The stock ended the day 0.50% lower at 2.00. The share price has gained 92.31% from its 52 week low with a 52 week trading range of 1.04 - 2.55. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $1.91 is greater than its 200-day moving average of $1.86. Shares of ImmunoVaccine have fallen approximately 14.89 percent year-to-date.

Access RDI's ImmunoVaccine Inc. Research Report at:
https://rdinvesting.com/news/?ticker=IMV.TO

Our Actionable Research on Fennec Pharmaceuticals Inc. (TSX:FRX.TO), Aptose Biosciences Inc. (TSX:APS.TO), TSO3 Inc. (TSX:TOS.TO) and ImmunoVaccine Inc. (TSX:IMV.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com